Key result
Microcarrier-cultured CVI988/DF-1 vaccine provides ~94% protection in chickens, equivalent to the commercial vaccine.
Why the study?
MDV is difficult to grow in suspension culture, making vaccine production labor-intensive and costly using adherent primary chicken embryo fibroblasts.
Does MDV CVI988/DF-1 vaccine prepared by microcarrier suspension culture provide equivalent immune protection to traditional adherent cell culture vaccines in specific pathogen-free chickens?
Population
Chicken fibroblast cell line UMNSAH/DF-1 and specific pathogen-free chickens
Comparison
MDV CVI988/DF-1 vaccine by microcarrier suspension culture vs commercial CVI988/Rispens vaccine by adherent culture
Design
Preclinical experimental study with bird experiments
Authors
Loading...
Supports scalable MDV vaccine production in animal models; leaves open field validation in commercial poultry.
Does MDV CVI988/DF-1 vaccine prepared by microcarrier suspension culture provide equivalent immune protection to traditional adherent cell culture vaccines in specific pathogen-free chickens?
Absolute Event Rate: 94.4% vs 94.1%
Microcarrier suspension culture of DF-1 cells can produce an MDV vaccine with equivalent protective efficacy to traditional adherent cell culture methods, enabling large-scale bioreactor production.
Wen et al. (2018) studied Marek's disease. CVI988/DF-1 vaccine (microcarrier suspension culture) vs. Commercial vaccine CVI988/Rispens (adherent cell culture) was evaluated on Protective rate. The CVI988/DF-1 vaccine prepared by microcarrier suspension culture provided a protective rate of 94.4% in specific pathogen-free chickens, equivalent to the 94.1% rate of the commercial vaccine.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: